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Summary
Drugs of abuse activate the mesolimbic dopaminergic pathway. Genetic variations in the dopaminergic system may
contribute to drug addiction. Several processes are shared between cocaine and heroin addictions but some neurobiological
mechanisms may be specific. This study examined the association of 98 single nucleotide polymorphisms in 13 dopamine-
related genes with heroin addiction (OD) and/or cocaine addiction (CD) in a sample of 801 African Americans (315
subjects with OD ± CD, 279 subjects with CD, and 207 controls). Single-marker analyses provided nominally significant
evidence for associations of 24 SNPs) in DRD1, ANKK1/DRD2, DRD3, DRD5, DBH, DDC, COMT and CSNK1E. A
DRD2 7-SNPs haplotype that includes SNPs rs1075650 and rs2283265, which were shown to alter D2S/D2L splicing,
was indicated in both addictions. The Met allele of the functional COMT Val158Met was associated with protection from
OD. None of the signals remained significant after correction for multiple testing. The study results are in accordance
with the results of previous studies, including our report of association of DRD1 SNP rs5326 with OD. The findings
suggest the presence of an overlap in genetic susceptibility for OD and CD, as well as shared and distinct susceptibility for
OD in subjects of African and European descent.
Keywords: Dopaminergic pathway, polymorphism, heroin addiction, cocaine addiction, African Americans, DRD1,
DRD2, COMT Val158Met, rs5326, rs1075650, rs2283265
Introduction
Drug addiction is a chronic brain disease that is the product
of genetic, environmental and drug-induced factors (Kreek
et al., 2012). The genetic determinants likely include inter-
actions among multiple neurochemical systems, including the
dopaminergic pathway. Drugs of abuse activate the mesolim-
bic dopaminergic pathway and dopamine (DA) has been im-
plicated in all stages of drug addiction (Chiara et al., 2004).
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Cocaine inhibits DA reuptake by blocking the DA transporter
thus directly increasing DA synaptic levels. Heroin increases
DA levels indirectly by inhibiting GABA neurons in the ven-
tral tegmental area (VTA). Twin studies indicated that a large
proportion of variance in the vulnerability for drug depen-
dence is heritable (Kendler et al., 2000). Although cocaine
and heroin addiction share psychological processes and neu-
robiological substrates, they differ in their behavioral, psy-
chological and neurobiological mechanisms and have unique
environmental influences (Badiani et al., 2011; Peters et al.,
2013). In addition, many individuals are addicted to both the
drugs.
This study examined the association of variations in DA
pathway-related genes with heroin and/or cocaine addiction
in African Americans (AA). Although, there is a similar risk to
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develop drug addiction among different ancestral populations,
differences in linkage disequilibrium (LD) and allele frequen-
cies may suggest the existence of some distinct genetic risk
factors. AA are significantly under-represented in association
studies and this study should help to address this gap.
The genes selected for this study are encoding DA receptors
(DRD1–5), a DA transporter (DAT1, SLC6A3), enzymes in-
volved in DA synthesis and degradation (TH, DBH, DDC and
COMT) and regulators of DA signaling (ANKK1, CSNK1E
and PPP1R1B). DA is the endogenous ligand for two classes
of G protein-coupled DA receptors; the D-like receptors (D1
and D5) and the D2-like receptors (D2, D3 and D4). Tyrosine
hydroxylase (TH) produces L-DOPA that is in turn catalysed
to DA by DOPA decarboxylase (DDC). DA is degraded by
catechol-O-methyltransferase (COMT), which is a modu-
lator of prefrontal dopaminergic tone. The DA transporter
(DAT1, SLC6A3) mediates the synaptic reuptake of DA. DA
beta-hydroxylase (DBH) converts DA to norepinephrine thus
regulating the ratio of the two neurotransmitters. DARPP-32
(PPP1R1B, DA- and cAMP-regulated phosphoprotein, 32
kDa) is a key regulatory molecule in the dopaminergic signal-
ing pathway. The casein kinase 1 epsilon isoform (CSNK1E)
is a serine/threonine-selective phosphotransferase that regu-
lates dopaminergic signaling through DARPP-32. ANKK1
is located in close proximity to DRD2, and there is high
LD between SNPs) in both genes. The TaqIA polymorphism
(rs1800497) is located in the coding region ofANKK1. There
is a potential relationship between ANKK1 and the dopamin-
ergic system (Hoenicka et al., 2010).
Several association studies of DA-related genes with heroin
or cocaine addiction have been reported. ANKK1/DRD2
SNPs were associated with heroin or cocaine addiction/abuse
in different populations (Al-Eitan et al., 2012; Clarke et al.,
2014; Jacobs et al., 2013a; Lawford et al., 2000; Li et al., 2006;
Nelson et al., 2013; Perez de los Cobos et al., 2007; Shah-
moradgoli Najafabadi et al., 2005; Vereczkei et al., 2013; Xu
et al., 2004). In addition, DRD1 SNPs were associated with
heroin abuse in Caucasians and AA (Jacobs et al., 2013a,b), a
DBH SNP was associated with progressive OD in Han Chi-
nese (Xie et al., 2013), and CSNK1E SNPs were associated
with OD in subjects of European descent (Levran et al., 2008)
and Han Chinese (Wang et al., 2014). COMT variants have
been associated with cocaine addiction in AA (Lohoff et al.,
2008), and cocaine-induced paranoia in European Americans
(EA) and AA (Ittiwut et al., 2011). Two association studies of
cocaine dependence (CD) in a Spanish Caucasian sample that
included dopaminergic genes reported nominal significant
association of SNPs in DBH, SLC6A3 and TH (Fernandez-
Castillo et al., 2010; Fernandez-Castillo et al., 2013). A recent
GWAS of CD in EA and AA did not identify association with
SNPs in DA-related genes (Gelernter et al., 2013).
This study examined the association of variations in 13
DA pathway-related genes with heroin and/or cocaine addic-
tion in a sample of 801 American subjects of predominantly
African ancestry. The study is an extension of our previous
studies in this population with a larger sample, modified SNP
content and an additional cocaine addiction sample (Levran
et al., 2009, 2014b) and follows our association studies in sub-
jects with European ancestry (Levran et al., 2008, 2014a, c).
Materials and Methods
Subjects
The study sample (n = 801) was divided into three main sam-
ples based on addiction status and preferred drug of addiction
(heroin or cocaine) (Table 1). The control sample included
207 subjects. All subjects (n = 315) in the heroin addiction
sample (#1, “OD±CD”) were current addicts in methadone
maintenance treatment programs and reported heroin as their
drug of choice. This sample is composed of two subsamples:
(#1a) “OD only;” including subjects with no cocaine addic-
tion and current or past alcohol addiction (5%) (n= 138, 44%)
and (#1b) “OD + CD;” including subjects with current or
past CD, with or without AD (n = 177, 56%). All subjects
(n = 279) in the cocaine addiction sample (#2, “CD only”)
had current or past CD and reported cocaine as their drug of
choice. Some of them (29%) also had current or past AD and
none of them had OD. The sex ratios were 0.52, 0.37 and
0.37 females in the controls, “OD ± CD” and “CD only”
samples, respectively. The mean ages (± SD) when blood was
obtained were 33 ± 12, 49 ± 10 and 43 ± 7 years in the con-
trol, “OD ± CD” and “CD only” samples, respectively. The
age range was 18–76 years. Cannabis use/abuse was assessed
but was not taken into account in the present analysis.
This study is an expansion of our previous study of OD
in AA (Levran et al., 2009) for which we added 481 new
subjects. Most subjects were self-identified as AA and showed
> 50% African ancestry contribution by STRUCTURE
analysis (see below). A total of 46 subjects who self-identified
as AA were excluded because they showed < 50% African
ancestry contribution. Seventy subjects whose self-identified
ancestry was different from AA (ambiguous, Caribbean
African non-Hispanic, European or Native American) were
included based on > 50% African ancestry contribution.
Hispanic subjects were not included.
Ascertainment was made by extensive personal interview,
using the following instruments: the Addiction Severity
Index (McLellan et al., 1992), the Kreek-McHugh-
Schluger-Kellogg Scale (KMSK) (Kellogg et al., 2003) and
the Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV).
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Table 1 Groups description.
Sample Diagnosis
# Drug Symbol 1 2 n f
1 Heroin “OD ± CD” 315
1a “OD only” 138 0.44
OD# – 123 0.39
OD# AD1 15 0.05
1b “OD + CD” 177 0.56
OD# CD1 76 0.24
OD# CD1/AD1 101 0.32
2 Cocaine “CD only” 279
CD1 – 198 0.71
CD1 AD1 81 0.29
3 Control – – 207
OD, heroin addiction; CD, cocaine addiction; AD, Alcohol addiction; n, number of subjects; f, frequency; #, current, 1, past and current.
Subjects were excluded from the control category with (1)
>1 instance of drinking to intoxication or any illicit drug use
in the last month; (2) a history of alcohol drinking to intoxica-
tion or illicit drug use more than twice a week for more than
six consecutive months and (3) cannabis use for more than 12
days in the last month or past cannabis use for > 2 days/week
for > 4 years. The former heroin addicts had a history of >
1 year of daily multiple uses of heroin and were treated at a
methadone maintenance treatment program (MMTP).
Subjects were recruited at the Rockefeller University
Hospital, the Manhattan Campus of the VA New York
Harbor Health Care System and the Dr. Miriam and Sheldon
G. Adelson Clinic for Drug Abuse Treatment and Research
in Las Vegas (LV), NV. The Institutional Review Boards
of the Rockefeller University Hospital and the VA New
York Harbor Healthcare System approved the study. The
Rockefeller University IRB also reviews the Adelson Clinic,
LV. All subjects signed informed consent for genetic studies.
Genes/SNPs and Genotyping
A new custom array (GS0013101-OPA) was designed based
on the “addiction” array (GS0007064-OPA; Illumina, San
Diego, CA, USA) (Hodgkinson et al., 2008) that was used in
our previous studies (Levran et al., 2008; Levran et al., 2009).
The original design included tagging SNPs with a minor
allele frequency (MAF) > 0.005 that aimed to capture the
full haplotype information of the HapMap Yoruban (YRI)
population (Hodgkinson et al., 2008).
Table 2 Dopaminergic pathway genes analysed in the study.
Symbol Name
ANKK1 Ankyrin repeat and kinase domain containing 1
COMT Catechol-O-methyltransferase
CSNK1E Casein kinase 1, epsilon
DBH Dopamine beta-hydroxylase
DDC DOPA decarboxylase
DRD1 Dopamine receptor D1
DRD2 Dopamine receptor D2
DRD3 Dopamine receptor D3
DRD4 Dopamine receptor D4
DRD5 Dopamine receptor D5
PPP1R1B Protein phosphatase 1, regulatory (inhibitor)
subunit 1B (DARPP-32)
SLC6A3 Solute carrier family 6 member 3 (dopamine
transporter, DAT)
TH Tyrosine hydroxylase
The 13 genes associated with the dopaminergic pathway
in this array were included in this analysis (Table 2). X
chromosome genes (e.g., MAOA) were not included. Based
on current HapMap data for the YRI sample, the mean gene
coverage for 10 of the genes is  70%. For three genes
(DRD4, DRD5 and PPP1R1B) there is not enough data to
calculate the % coverage.
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Fourteen SNPs from these genes were excluded from the
new array based on low quality in the original array, and 19
SNPs were excluded based on low MAF in the population
of this study. Nine SNPs were added, based on functionality
or reports of association with related phenotypes, including
three ANKK1 SNPs, with a total of 118 SNPs (Table S1).
Genotyping was performed using an Illumina GoldenGate
Custom Panel of 1536 SNPs at the Rockefeller University
Genomics Resource Center. Random samples were geno-
typed in duplicate. Analysis was performed with BeadStudio
software v2.3.43 (Illumina) and all cluster plots were manually
inspected.
Assessment of Percentage of African Ancestry
Using Ancestry Informative Markers (AIMs)
A set of 155 AIMs was used for STRUCTURE 2.2 anal-
ysis (Pritchard et al., 2000). Biographic Ancestry Scores
(e.g., fractions of genetic affiliation of the individual in
each cluster) were estimated under the assumption of seven
clusters (k). Each subject was anchored against genotypes
of 1051 samples from the Human Genome Diversity Cell
Line Panel (www.cephb.fr/en/hgdp panel.php), as described
(Ducci et al., 2009). To be included in the study, an individual
had to show > 50% African ancestry contribution.
Statistical Analysis
The statistical power was estimated for the different case sam-
ples with the standard test for difference between proportions,
under additive, dominant or recessive logistic regression mod-
els, assuming odds ratios (OR) between 1.2 and 2.2 and MAF
within the range 0.05–0.45, at a fixed significance level of 0.05
and power = 0.80 (Sham & Purcell 2014). The same control
sample size (n = 207) was used in each calculation. All sam-
ples have sufficient power to detect ORs as low as 1.2 for a
SNP with MAF as high as 0.45. For SNPs with MAF as low
as 0.05, the combined sample (“OD ± CD” & “CD only”,
n = 594) can detect ORs as low as 2.0, the “OD ± CD”
sample (n = 315) can detect OR as low as 2.2 and the “CD
only” sample (n = 279) can detect OR as low as 1.8. The
“OD only” sample of (n = 138) can detect OR as low as 2.1
for a SNP with MAF as low as 0.1.
Deviation from Hardy–Weinberg equilibrium (HWE) was
examined in the control sample by the exact test using the
PLINK program (Purcell et al., 2007). Pairwise LD and LD
blocks were estimated using Haploview 4.2 (Barrett et al.,
2005), based on the ‘Solid Spine of LD’ algorithm.
Association analyses were performed by two approaches:
(1) A one-way ANOVA and logistic regressions were per-
formed using the R package, with four samples as a cat-
egorical variable: (a) “OD only” #1a, (b) “OD + CD”
#1b, (c) “CD only” #2 and (d) control. The number of
major alleles or a binary variable for dominant and reces-
sive model was the dependent variable for ANOVA and
logistic regressions, respectively. F-test or χ2 was used to
test the significance of the model in ANOVA and logis-
tic regression, respectively. P-values from ANOVA and
logistic regression were corrected according to the
Benjamini-Hochberg methodology (FDR). Post-hoc pair-
wise comparisons were performed for the significant as-
sociations.
(2) Independent logistic regression analyses were performed
for the “OD ± CD”, “OD only”, “CD only” and “OD
± CD” + “CD only” samples. Logistic regression was
performed for each SNP separately using the case-control
framework in PLINK, and as two groups reflecting domi-
nant or recessive inheritance models. The direction of the
regression coefficient represents the minor allele. Sex was
included as a covariate in the initial model but had no
significant effect on the results, so it was not included in
the final analysis. Adjustment for multiple testing was also
performed by permutation test (n = 100,000) for each
model of inheritance using PLINK.
Results
Case-control association analysis was conducted in 801 sub-
jects (315 subjects with heroin addiction, with or without
cocaine or alcohol addiction, 279 subjects with cocaine ad-
diction, with or without alcohol addiction and 207 controls)
(Table 1). The heroin sample (#1) is comprised of two sub-
samples: #1a, “OD only,” including subjects with no past
or current CD (n = 138) and #1b, “OD + CD,” including
subjects with current or past CD (n = 177). One hundred
and eighteen SNPs from 13 genes related to the dopamin-
ergic pathway were genotyped (Tables 2 and S1). Twenty
SNPs were excluded based on low quality. The remaining 98
SNPs were analysed separately for association with heroin or
cocaine addiction. One SNP (ANKK1 rs7118900) showed
significant deviation from HWE in controls (P = 0.007) and
the rest of the SNPs showed no significant deviation (P >
0.01). There was no evidence for population substructure
among the three samples (heroin, cocaine and controls) based
on STRUCTURE analysis of 155 AIMs. There was an av-
erage of 81 ± 10% African ancestry and similar admixture
pattern among the samples, as was shown in our previous
study of this cohort (Levran et al., 2014b). Analysis of LD
indicated 26 haplotype blocks, including 17 highly correlated
(r2 > 0.7) SNPs (seven pairs and one triplet) (Table S2 and
Fig. S1).
ANOVA and logistic regression assuming four categories:
(#1a) “OD only,” (#1b) “OD + CD,” (2) “CD only”
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Table 3 Nominally significant associations using logistic regression.
P1
“OD“OD only”“CD only”LocationSNPGene ± “ODCD” ± ORModelCD” & 2 L953 U954
“CD only”
1 & 21a & 1b1a2
DRD1 3’ UTRrs686 0.014 2.351.101.61D0.031
rs5326 5’ UTR 0.006 D 1.87 1.16 3.02
ANKK1 rs71189005 Ala239Thr 0.008 0.006 0.010 R 0.49 0.29 0.81
DRD2 rs1076560 Intron 0.038 0.047 D 1.78 1.03 3.08
rs2283265 Intron 0.038 0.047 D 1.78 1.03 3.08
rs25875486 Intron 0.022 0.005 0.018 D 0.51 0.32 0.81
rs10765636 Intron 0.032 0.011 0.043 D 0.55 0.35 0.87
rs1079596 Intron 0.007 0.006 0.019 0.005 D 1.63 1.16 2.29
rs1125394 Intron 0.011 0.010 0.028 0.009 D 1.58 1.12 2.21
rs2471857 Intron 0.045 0.029 0.029 D 1.48 1.04 2.10
rs4648318 Intron 0.039 R 1.58 1.02 2.45
rs4274224 Intron 0.025 R 2.14 1.10 4.16
rs1799978 Intron 0.017 0.029 D 1.64 1.09 2.46
DRD3 rs3773678 Intron 0.016 R 2.17 1.16 4.07
rs167771 Intron 0.007 0.012 0.048 R 4.83 1.53 15.31
DRD5 rs2867383 Downstream 0.031 0.013 0.010 D 0.64 0.46 0.90
DBH rs1108580 Glu162= 0.042 0.046 R 0.58 0.34 0.98
DDC rs2122822 Intron 0.046 D 0.67 0.45 0.99
rs2329341 Intron 0.031 D 0.68 0.48 0.97
COMT rs933271 Intron 0.039 R 1.68 1.03 2.75
rs2239393 Intron 0.047 D 1.65 1.01 2.71
rs4818 Leu126= 0.002 D 1.98 1.27 3.07
rs4680 Val158Met 0.043 R 0.38 0.15 0.97
CSNK1E rs5757037 Upstream 0.012 D 1.78 1.14 2.77
P-Value in bold are the lowest obtained for the speciﬁc SNP; Dash lines box represents haplotype block.
D, dominant; R, recessive; Chr, chromosome; OR, odds ratio.
1The lowest nominal P value obtained from testing two models of inheritance: dominant and recessive. Empty cells indicate P 0.05.
2OR for the lowest P value for this SNP. OR < 1 represent protective effect of the minor allele, OR > 1 represents risk. effect of the minor
allele.
395% conﬁdence interval lower value.
495% conﬁdence interval upper value.
5This SNP showed signiﬁcant deviation from HWE in controls (P = 0.007).
6These SNPs were associated with heroin addiction in subjects with European ancestry (Levran et al. 2014c).
and controls, revealed 16 SNPs with nominally significant
differences among the groups under at least one model
of inheritance (Table S3). None remained significant after
correction for multiple testing. Post hoc pairwise comparisons
of these SNPs revealed nominally significant differences of
11 SNPs, including five SNPs (ANKK1 rs7118900, DRD2
rs1079596 and rs2587548, DRD3 rs167771 and COMT
rs4818) between the control sample and the “OD only”
sample, one SNP (CSNK1E rs5757037) between “CD
only” and “OD only”, and two SNPs (COMT rs2239393
and rs4818) between the “OD only” sample and “OD +
CD” sample (Table S3). None remained significant after
correction for multiple testing.
Logistic regression under two models of inheritance (dom-
inant/recessive) for “OD only” (1a), “OD ± CD” (1a &1b),
the “CD only” (2) and “OD ± CD” & “CD only” (1 and
2) samples, revealed nominally significant differences in geno-
type frequencies for 24 SNPs in nine genes (DRD1, ANKK1,
DRD2,DRD3, DRD5, DBH,DDC,COMT andCSNK1E)
(Table 3). No signal survived correction for multiple testing.
Of those, four SNPs (in ANKK1, DBH and COMT) are
coding SNPs (two non-synonymous and two synonymous).
LD analysis showed that some of these SNPs are part of
three haplotype blocks, including seven DRD2 SNPs, DRD1
SNPs rs686 and rs5326, as well as COMT SNPs rs2239393
and rs4818, respectively. Among the DRD2 haplotype block
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Figure 1 DRD2 P airwise linkage disequilibrium. The pairwise correlation between SNPs was measured as
‘D’ (A) or r2 (B). The values are shown (x100) in each box. The color scheme indicates the magnitude of the
value. When the value is equal to 1.0 no number is given.
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there are two SNP pairs and one triplet in strong correlation
(r2 > 0.72) (Table 3, Fig. 1, Table S2 and Fig. S1).
The comparison of results of the different analyses indi-
cated several SNPs that were only detected in a specific sam-
ple (e.g., “OD only”) and SNPs for which the P-values were
lower in the “OD only” or “CD only” compared with other
samples, despite the smaller sample size (Table 3). Other SNPs
showed lower signals in the combined addiction group includ-
ing DRD2 and DRD5 SNPs.
The association signal, under the recessive model, of the
functional COMT SNP rs4680 (Val158Met) was driven
by lower frequency (0.04) of the AA genotype (encoding
Met/Met) in the “OD only” group than in the control group
(0.11) indicating a protective effect (OR = 0.38; 95% CI
0.15–0.97) (Table S4).
Discussion
This study provides evidence for nominally significant associ-
ations of several SNPs in genes involved in the dopaminergic
pathway with heroin and/or cocaine addiction in AAs. This
study can be viewed as a major expansion of our previous
study of OD in AAs (Levran et al., 2009). The genes included
in the current study, except for ANKK1, were included in
the previous study, although the SNP content was modified
to exclude redundant and non-informative markers and to
include additional SNPs. We have not previously studied
cocaine addiction in this cohort.
The two DRD1 SNPs identified in association with heroin
and/or cocaine addictions are located in the 5’ and the 3’
UTR of the gene, respectively. They are in the same hap-
lotype block, but they are not strongly correlated (r2 < 0.2)
in both African and European populations. SNP rs5326 has a
comparable allele frequency in different populations (0.14–0.2
in HapMap CEU, YRI and CHB). DRD1 rs686 is located in
a sequence complementary to the seed sequence of miR-504
and showed differential expression of the two variants (Huang
& Li, 2009). The study results are in accordance with our pre-
vious finding of association of DRD1 SNP rs5326 with OD
in AA (Levran et al., 2009). It is also in line with a study
showing association of this SNP with time to develop heroin
dependence in Han Chinese (Peng et al., 2013). DRD1 SNP
rs686 was associated with nicotine dependence in AA (Huang
et al., 2008) and AD in Europeans (Batel et al., 2008). It was
also associated with duration of transition from the first use
to OD in Han Chinese (Zhu et al., 2013) and with opioid
abuse in AA (Jacobs et al., 2013b).
One ANKK1 SNP and 10 DRD2 SNPs showed associa-
tion with heroin and/or cocaine addiction, including seven
SNPs that are part of one haplotype block, suggesting a re-
lated signal. The non-synonymous ANKK1 SNP rs7118900
(Ala239Thr) identified in this study is in perfect LD with
SNP rs1800497 (TaqIA) in the HapMap European popu-
lation (CEU), but in low LD (r2 < 0.2) with this SNP
in the HapMap African population (YRI) suggesting a po-
tentially different effect of this SNP on DRD2 expression.
SNP rs1800497 was excluded from this analysis based on low
quality. The association of ANKK1 SNP rs7118900 should
be interpreted with caution since the SNP showed significant
deviation from HWE in the control sample, although there
was no indication of low genotyping quality and this SNP
was in HWE in another control sample of European ances-
try that was genotyped with the same array (Levran et al.
2014c). An in vitro study showed differential gene expression
of the two variants of SNP rs7118900 at baseline and in re-
sponse to stimulation with apomorphine. The variant 239Thr
is predicted to create a new phosphorylation site (Garrido
et al., 2011). DRD2 has two major splice isoforms with dis-
tinct functions: D2 long (D2L) and D2 short (D2S). The
DRD2 SNPs rs1076560 and rs2283265, that are in perfect
LD were shown to shift splicing from D2S to D2L, changing
their expression ratio. These variants were associated with dif-
ferences in brain functions and psychiatric disorders (Zhang
et al. 2007, Moyer et al., 2011).
Previous association studies of DRD2 with heroin and co-
caine addictions produced mixed results that may be partly
explained by small sample size, population substructure and
suboptimal ascertainment (for additional references and dis-
cussion see Moyer et al., 2011). The results of this study are
compatible with several studies. DRD2 SNPs rs2283265 and
rs10765560 were associated with OD in a Jordanian sample
(Al-Eitan et al., 2012) and in Europeans (Jacobs et al., 2013a).
They were also associated with cocaine abuse and depen-
dence in EA (Moyer et al., 2011). SNP rs10765560 has been
recently associated with OD, but not with CD, in European
and AA (Clarke et al., 2014). Of note, the OD sample used
by Clarke et al. includes a substantive number of DNA sam-
ples from our laboratory that are part of the NIDA Center
for Genetic Studies DNA Repository, so it cannot be con-
sidered an independent sample. DRD2 SNP rs1079597 (also
called “TaqIB”) has been previously associated with heroin
dependence in a Hungarian sample (Vereczkei et al., 2013).
Although this SNP was not included in the study, it is in
strong LD, in the HapMap African sample (YRI), with SNP
rs1076560. DRD3 SNP rs167771 indicated in this study was
previously associated with nicotine dependence (Wei et al.,
2012), smoking behaviour (Yu et al., 2006) and autism (Toma
et al., 2013).
The functional rs4680 (Val158Met), identified in this study
in association with OD, is one of the most well-studied SNPs
(Montag et al., 2012; Tammimaki & Mannisto 2010). The
frequency of the A allele (encoding Met) and the AA geno-
type was lower in subjects with OD (without CD), compared
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with controls or subjects with CD or OD + CD. This allele
is associated with lower enzymatic activity, higher dopamine
levels, enhanced vulnerability to stress as well as increased sus-
ceptibility to white matter structural alterations in the context
of addiction (Zhang et al., 2013). It was associated with CD
in AA (Lohoff et al., 2008) and cocaine-induced paranoia in
EA and AA (Ittiwut et al., 2011). It has been suggested that
environmental factors impact the detection of small effects of
this variant on alcohol addiction vulnerability (Schellekens
et al., 2012). COMT SNPs rs4680 and rs933271, indicated
in this study, were predicted to have potential functionality
based on a signature of positive selection in EA and AA
(Ittiwut et al., 2011). SNP rs737866 that was associated with
earlier age of opiate onset in Chinese (Li et al., 2012), is in
strong LD (Dʹ = 0.85) with SNP rs933271 in this sample.
The suggested association of a SNP upstream of CSNK1E
with OD is intriguing since we have found association of an-
other CSNK1E SNP and haplotype with OD, in EA (Levran
et al., 2014c) and yet another SNP was associated with OD
in Han Chinese (Wang et al., 2014). There is no LD be-
tween these SNPs in this sample and no information on the
SNP identified. CSNK1E interacts with circadian rhythms
and DARPP-32 and has been implicated in negative regula-
tion of sensitivity to opioids in rodents (Bryant et al., 2012;
Cheong & Virshup 2011).
DDC SNP rs2329341 that was indicated in this study was
recently shown to be associated with CD subtype, by inter-
acting with aGABRG3 SNP (Bi et al., 2014). A recent report
suggested an association of DBH SNP rs1611115 with pro-
gressive OD in Han Chinese (Xie et al., 2013). This SNP was
included in this study but did not show significant association.
Cocaine vs. Heroin Addiction
The model of common (non-drug specific) susceptibility
to addiction hypothesises the presence of a non-specific
susceptibility to all drug addictions based on shared biological
mechanisms and high genetic correlations between suscep-
tibilities to specific drug addictions (Vanyukov et al., 2012).
Decrements inDRD2 receptors in the striatumwere observed
in addicts to several drugs of abuse (Koob & Volkow, 2010).
Although cocaine and heroin addiction share psychological
processes and neurobiological substrates, they differ in neuro-
biological mechanisms and environmental influence (Badiani
et al., 2011; Peters et al., 2013). For example, chronic heroin
or cocaine abusers showed unique gene expression profiles in
the postmortem nucleus accumbens (Albertson et al., 2006).
In this study, we have analysed different combinations of
heroin and cocaine addiction, in order to identify SNPs with
either drug-specific or non-drug-specific effect. Comparison
of the association signals in the different samples suggest
several shared signals (e.g. DRD2 SNPs rs1079596 and
rs1125394) that might reflect an association with a general
phenotype of substance addiction and also signals that might
be unique to the CD orOD (e.g.,COMT rs4680 Val158Met).
European vs. AA (Heroin Addiction)
Although heroin and/or cocaine addiction have similar
prevalence in different ancestral populations, these popula-
tions may have distinct as well as shared genetic risk factors.
The causes for the distinct factors may include different
allele frequencies, LD patterns, modifier genes and/or
gene-environment interactions.
We have reported association analyses of OD using a
similar marker set in subjects of predominantly European
ancestry (Levran et al., 2008, 2014c). Comparison of the
findings in the two ancestral populations reveals mostly
distinct polymorphisms. We have reported an association
of the casein kinase 1ε gene CSNK1E SNP rs1534891
and related haplotype, with OD in subjects with European
ancestry. This SNP was not indicated in this study, although
that may be partly explained by the low MAF of this SNP
in African populations. This study indicated the common
SNP rs5757037 in association with OD, but this SNP was
not identified in EA. There is no LD between these SNPs.
Nevertheless, in both populations there were common
association signals in DRD2 (rs1076563 and rs2587548).
Although the two DRD2 SNPs are in strong LD in both
populations, their allele frequency is different and their minor
alleles in EA are the major alleles in AA. Another potential
common association is theDRD2 SNP rs1076560. This SNP,
and SNPs in strong LD with this SNP, were associated with
OD in subjects with European ancestry by other groups (Ja-
cobs et al., 2013a; Vereczkei et al.; 2013; Clarke et al., 2014).
The general LD pattern of the ANKK1/DRD2 region
is different between the two populations. Thus, the ANKK1
SNP rs7118900, which was identified in this study, is in strong
LD with the two DRD2 SNPs mentioned above and the
ANKK1 SNP rs1800497 (TaqIA) only in population of Eu-
ropean ancestry, suggesting a potentially different effect of this
SNP on gene expression. There is no LD between theDRD3
SNPs indicated in EA and AA.
Some limitations should be considered when interpret-
ing the results of this study. Although nominally significant,
the associations may be due to chance and further testing in
independent populations and/or meta-analysis is needed for
confirmation. The study is underpowered to detect variants
with small effects and it is possible that significant associa-
tions were not detected because of limited power due to the
sample size and partial gene coverage. Although there was no
indication of population substructure between cases and con-
trols, the admixed nature of the AA populations could be a
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source of error for SNPs that differ in their allele frequencies
between the two ancestral populations. In addition, because
of the high substance-related comorbidity and the study de-
sign, the labelling of shared or common susceptibility may
not be accurate. Despite these limitations, the study has im-
portant strengths, including rigorous ascertainment, reliable
phenotype data and stringent inclusion/exclusion criteria.
In summary, this study provides evidence for nominally sig-
nificant associations of specific variants in DA-related genes
with heroin and cocaine addictions that are common and/or
specific to the AA population. AAs are significantly under-
represented in association studies and this study helps to ad-
dress this gap. The findings suggest the presence of both shared
and distinct genetic susceptibility for heroin and cocaine ad-
dictions as well as for African and European Americans. Sev-
eral SNPs of potential importance were indicated and further
studies are warranted to confirm the results.
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